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OBJECTIVE — To gather preliminary data on the feasibility and efﬁcacy of etanercept ther-
apy to prolong endogenous insulin production in pediatric patients with newly diagnosed type
1 diabetes.
RESEARCH DESIGN AND METHODS — This was a 24-week double-blind, random-
ized, placebo-controlled study conducted at the Diabetes Center, Women and Children’s Hos-
pital of Buffalo. Eighteen subjects (11 male and 7 female, aged 7.8–18.2 years) were randomly
assigned to receive either placebo or etanercept. Inclusion criteria included age 3–18 years,
GAD-65 and/or islet cell antibody positivity, A1C 6%, three insulin injections per day, white
blood cell count 3,000–10,000, platelets 100,000, and normal liver and renal function.
Intention-to-treat analysis was used.
RESULTS — A1C at week 24 was lower in the etanercept group (5.91  0.5%) compared
with that in the placebo group (6.98  1.2%; P  0.05) with a higher percent decrease from
baseline than in the placebo group (etanercept 0.41  0.1 vs. placebo 0.18  0.21; P  0.01).
The percent change in C-peptide area under the curve from baseline to week 24 showed a 39%
increase in the etanercept group and a 20% decrease in the placebo group (P  0.05). From
baseline to week 24 insulin dose decreased 18% in the etanercept group compared with a 23%
increase in the placebo group (P  0.05). Seventeen patients completed the study, and none
withdrew because of adverse events.
CONCLUSIONS — Inthissmallpilotstudy,treatmentofpediatricpatientsnewlydiagnosed
with type 1 diabetes with etanercept resulted in lower A1C and increased endogenous insulin
production, suggesting preservation of -cell function. A larger study is needed to further
explore safety and efﬁcacy.
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T
ype 1 diabetes is a T-cell–mediated
autoimmune disease characterized
by selective destruction of insulin-
producing -cells within the pancreatic
islet. This chronic disease affects 1 in
400–600 youth and poses a signiﬁcant
medical and psychological burden on pa-
tients and their families (1–3). In most
patients, diagnosis and treatment are fol-
lowed by a “partial remission period”
(honeymoon period) during which tran-
sientpartialrecoveryofendogenousinsu-
linproductionoccurs.Eventually,thereis
progressive, irreversible -cell demise,
leaving the patient totally dependent on
exogenous insulin administered via mul-
tiple daily injections or continuous sub-
cutaneous insulin infusion. Thus, the
partial remission period represents a win-
dow of opportunity to halt the progres-
sionofthedisease.Severalclinicalstudies
arecurrentlyconductedtotestagentsthat
may alter the natural history of type 1
diabetes.
Tumor necrosis factor- (TNF-)
and other cytokines play a role in the au-
toimmune process leading to pancreatic
destruction (4,5). Evidence suggesting
that TNF- plays an active role in the
pathogenesis of type 1 diabetes is derived
from in vitro studies and animal models.
In the nonobese diabetic mouse, TNF-




that TNF- potentiates the direct func-
tional inactivation and destruction of
-cells by other cytokines such as
interleukin-1 and interferon- (7–11).
Transgenic mice with increased -cell ex-
pression of TNF- have signiﬁcant lym-
phocyticinsulinitis,whichisabrogatedin
TNF receptor–null mice (12). These ﬁnd-
ings support the role of TNF- in signal-
ing lymphocytic invasion, promoting
local inﬂammation within pancreatic is-
letsandcontributingtocytokine-induced
-cell destruction.
Etanercept is a recombinant soluble
TNF- receptor fusion protein that binds
to TNF-. It acts by clearing TNF- from
the circulation, thereby blocking the bio-
logical activity of this inﬂammatory cyto-
kine. Although etanercept is used in the
treatment of many autoimmune diseases
including ankylosing spondylitis, juve-
nilerheumatoidarthritis,psoriasis,psori-




tion of etanercept to children newly diag-
nosed with type 1 diabetes may prolong
the partial remission period. The aim of
this pilot study was to gather preliminary
data on the feasibility and efﬁcacy of et-
anercept administration to pediatric pa-
tients with recently diagnosed type 1
diabetes. The primary end points of this
study were percent change from baseline
for A1C and for C-peptide area under the
curve (AUC). Secondary end points were
insulin dose change from baseline and
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ued, if any.
RESEARCH DESIGN AND
METHODS— This was a random-
ized, double-blind, placebo-controlled
feasibility study lasting 24 weeks, fol-
lowed by a 12-week washout period. In-
clusion criteria were as follows: male and
femalesubjectsaged3–18yearswithtype
1 diabetes, GAD-65 and/or islet cell anti-
body positivity, A1C 6% at diagnosis,
insulin regimen with three injections
daily, white blood cell count between
3,000 and 10,000 and platelets
100,000, normal alanine aminotrans-
ferase and aspartate aminotransferase,
creatinine 1.8 mg/dl, and type 1 diabe-
tes duration 4 weeks. However, to ac-
commodate parental schedules, this
window was lengthened, resulting in a
1.7- to 5.7-week interval between diabe-
tes diagnosis and baseline. Exclusion
criteria were as follows: intravenous anti-
biotics at diagnosis or within 14 days of
studyentry,BMI85thpercentileforage
and sex, unstable household unable to
comply with study protocols, evidence of
psychiatric disease in the study subject
and/or primary caretaker, and chronic
disease, including additional autoim-
mune disorders with the exception of eu-
thyroid autoimmune thyroiditis. The
study was approved by the institutional
review boards of the Women and Chil-
dren’s Hospital of Buffalo and the Univer-
sity at Buffalo and was conducted in
accordance with the Declaration of Hel-
sinki. Subjects and their parents signed
informed consent and assent forms.
All patients received a three-injection
insulin regimen with Humalog and NPH
before breakfast, Humalog before dinner,
and NPH at bed time. Patients were in-
structed to measure blood glucose by ﬁn-
gerstick before breakfast, lunch, and
dinner, at bed time, and at 2:00 A.M.a s
needed and when having symptoms of
hypoglycemia. Insulin adjustments were
made throughout the study at clinic visits
andbytelephoneore-mailbetweenstudy
visits.
Study visits occurred every 4 weeks
during the study drug period and 4 and
12 weeks after discontinuation of the
study drug. Randomization was stratiﬁed
based on an A1C level of 9.5% at diagnosis.
Study subjects were randomly assigned
in a 1:1 ratio to subcutaneous injections
of placebo or etanercept. The study drug,
provided by Immunex/Amgen, was ad-
ministered at a dose of 0.4 mg/kg up to a
maximumdoseof25mg/dosesubcutane-
ously twice weekly (Monday/Thursday,
Tuesday/Friday, or Wednesday/
Saturday). The study drug was stored in
the pharmacy of the Women and Chil-
dren’s Hospital of Buffalo and reconsti-
tuted with 1 ml of bacteriostatic water by
the pharmacist, according to the master
randomization table provided by Immu-
nex/Amgen. Every 4 weeks, parents were
provided with preﬁlled and refrigerated
syringes of the study drug and returned
empty syringes.
The study procedure at every visit in-
cluded laboratory work (cell blood
counts, biochemical proﬁle including
liverandkidneyfunctiontests,andA1C),
clinic visit (physical examination, blood
glucose review, and insulin adjustment),
and study drug dispensation. Menstruat-
ing female subjects also had urine human
chorionic gonadotropin measurements.
Figure 1—Flow diagram showing the progress of the patients throughout the trial.
Mastrandrea and Associates
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1245An antinuclear antibody (ANA) titer was
obtained at baseline, at weeks 12 and 24
of treatment, and at week 12 of washout.
Atbaselineandweek24,aBoostmealtest
wasperformed(6ml/kguptoamaximum
of 360 ml). C-peptide was measured at 0,
30, 60, and 120 min, and AUC was cal-
culated using the trapezoidal rule (15).
Thecellbloodcountanddifferential,bio-
chemical proﬁles, A1C, and ANA titer
were performed in the laboratory of the
Women and Children’s Hospital of Buf-
falo (Kaleida Health). The A1C was
measured by high-performance liquid
chromatography with Bio-Rad variant
(Bio-Rad, Richmond, CA). C-peptide was
measured by immunoassay; islet cell an-
tibodies and GAD-65 antibodies were
measured by radiobinding at Nichols In-
stitute laboratory (San Juan Capistrano,
CA).
Preliminarydatawerenotavailableto
perform power calculations. Historically,
interventions that result in a change in
A1C of 1% (SD 1.0) are accepted as
clinicallyrelevant.Aprioripoweranalysis
indicated that a total sample size of 30
subjects (15 control and 15 treatment)
would have 86% power to detect a 1%
difference in A1C level (SD  1.0) after
24 weeks of treatment (0.05; effect
size  1.1). Because of the slow recruit-
ment, the principal investigator decided
to halt the study before reaching the
planned number of participants. The
principalinvestigatorthoughtthatifthese
preliminary results were favorable, they
could be used as a basis for a larger efﬁ-
cacy and safety study to be proposed to
TrialNet.
Data are means  SD with the excep-
tion of Fig. 2, for which values are
means  SEM. Comparisons between
groupsateachtimepointwereperformed
usingtheWilcoxon-Mann-Whitneyexact
method test. This method was used be-
causeofthesmallsamplesizeandthefact
that it does not rely on large sample size
approximation. Note that the linear
model–based method was not used to
handle repeated measures as this approach
is reliable only for large samples. Kendall’s
tau-b coefﬁcient was used to test for associ-
ations between numerical outcomes. All
statistical analyses were conducted using
SAS (version 9.1). An intention-to-treat
analysis was performed.
RESULTS— Nineteen patients and
their parents signed informed consent or
assent forms. An intention-to-treat analy-
sis was performed for the data of the 18
randomly assigned patients (Fig. 1). The
characteristics of study participants at
baselinewerenotstatisticallydifferentbe-
tween groups (Table 1). Study protocol
institutional review board and Food and
Drug Administration procedures were in
place in June 2002; the study took place
between October 2002 and October
2007. Reasons for slow recruitment were
1) parental concern over potential side ef-
fects and 2) lack of a “stable household
environment,” which was necessary to





cent decrease throughout the study. A1C
values were higher in the etanercept than
in the placebo group at both baseline and
week 4 of treatment (difference not statis-
tically signiﬁcant). From week 8, the A1C
values were lower in the etanercept
group,withstatisticalsigniﬁcanceatweek
24 in etanercept group (5.91  0.5%)
compared with the placebo group
(6.981.2%;P0.05)(Fig.2A).More-
over, from week 8 through week 24 of
treatment, the percent decrease in A1C
from baseline was consistently higher in
favor of the etanercept group (Fig. 2B).
The A1C values continued to be lower in
the etanercept group than in the placebo
group at the 4- and 12-week washout ob-
servations, but this value reached statisti-
cal signiﬁcance only at the 4-week
washout visit (P  0.05) (Fig. 2A). How-
ever,thepercentA1Cdecreasefrombase-
linecontinuedtobestatisticallygreaterin
the etanercept group than in the placebo
group at both week 4 and week 12 of
washout (Fig. 2B).
Blood glucose levels before breakfast,
dinner, and bedtime for a 7-day period
preceding baseline and week 24 were
similar at baseline between the groups. At
week 24, they demonstrated a trend to-
ward lower blood glucose averages for
fasting (111  27 vs. 158  69 mg/dl;
P  0.18), before dinner (149  44 vs.
208  55 mg/dl; P  0.054), and before
bedtime (129  24 vs. 198  46; P 
0.01) in the etanercept and placebo
groups, respectively.
C-peptide AUC in the etanercept
group increased from 3.1  1.2 ng   ml
	1  
h
	1 at baseline to 3.9  1.6 ng   ml
	1  
h
	1 at week 24, whereas in the placebo
group it decreased from 4.7  2.2 ng  
Figure2—A1Cvalues(A)andrelativechange
in A1C (B) throughout a 24-week treatment
and 12-week washout period for etanercept-
and placebo-treated groups. Values represent
means  SEM at each time point. *P  0.05;
∨ P  0.01.   , placebo; f, etanercept.
Table 1—Characteristics of study participants at diagnosis
Etanercept Placebo
Sex (male/female) 8/2 3/5
Age (years) 12.5  3.3 12.4  3.6
Height (cm) 154.4  18.3 152.1  16.6
Weight (kg) 51.1  19.7 49.2  15.9
Insulin (units   kg
	1   day
	1) 40.4  22.3 39.6  20.5
A1C (%) 12.8  3.2 12.4  2.5
C-peptide (ng/ml) 0.9  0.4 1.1  0.8
Diabetes duration (days) 21.4  4.4 28.5  7.5
Data are means  SD.
Etanercept therapy in type 1 diabetes
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	1   h
	1 at baseline to 3.6  2.0 ng  
ml
	1   h
	1 at week 24. These changes
resulted in a mean relative percent in-
crease in C-peptide AUC from baseline to
week 24 of 39% in the etanercept group,
whereas the placebo group exhibited a
20% decrease compared with baseline
(P  0.05). In the etanercept group, all
subjects but one experienced stable or in-
creased C-peptide AUC, whereas in the
placebo group, all subjects but one
showed a decline in C-peptide AUC (Fig.
3).Therewasnoassociationbetweentype
1diabetesdurationandC-peptideorA1C
at either baseline or week 24.
The number of insulin injections in
theetanerceptandplacebogroupsdidnot
differ appreciably. However, the insulin
dose change between baseline and week
24 showed a mean decrease of 18% in the
etanercept group compared with a mean
increaseof23%intheplacebogroup(P
0.05). There was no association between
the relative difference in C-peptide and
insulin dose from baseline to week 24.
Safety data
There were no severe adverse events in
eithergroup.Thefrequencyofeventswas
similar in the two groups with the follow-
ing exceptions: three very mild episodes
ofself-resolvingparesthesiainonesubject
in the etanercept group and none in the
placebo group; cold symptoms, reported
twice as frequently in the etanercept
group compared with the placebo group;
and abdominal pain with six of nine epi-
sodes reported by one patient receiving
etanercept. None of these events caused
signiﬁcant disruption of daily activities or
signiﬁcant absence from school.
Results of cell blood count with dif-
ferential and biochemical proﬁle, includ-
ing liver and renal function tests were
unremarkableinthetwogroups.Thema-
jority of cell blood count or biochemical
proﬁle abnormalities were present at
baseline, were not clinically signiﬁcant,
and did not worsen during the study.
A positive ANA titer was detected at
baseline in ﬁve subjects assigned to etan-
ercept and two assigned to placebo. The
ANA titer results at baseline for one sub-
jectintheetanerceptgroupweremissing.
This subject had a positive ANA titer in
thesamplesdrawnthereafter.Noneofthe
subjectsintheetanerceptgroupwithneg-
ative results at baseline converted to pos-
itive ANA status, and one subject in the
placebo group converted to positive sta-
tus after discontinuation of study drug.
CONCLUSIONS — This is the ﬁrst
placebo-controlled pilot study to gather
dataonthefeasibilityofetanercepttopro-
long endogenous insulin production in
youth with new-onset type 1 diabetes. A
24-week course of etanercept adminis-
tered to pediatric patients with newly di-
agnosed type 1 diabetes resulted in lower
A1C in the etanercept group compared
with that in the placebo group at the end
of the treatment period, with a signiﬁ-
cantly different A1C percent change from
baselinefavoringtheetanerceptarm.This
ﬁnding was associated with a mean in-
Figure 3—C-peptide at baseline and 24 weeks for individual subjects. F, etanercept; E, placebo.
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AUC in response to a meal test in the et-
anercept group as opposed to a mean de-
crease of 20% observed in the placebo
group, which is similar to declines pub-
lished in the literature (16). Thus, both
primary end points of this trial were met.
In addition, glycemic levels during a
7-day period preceding the week 24 visit
showed a lower trend for the etanercept
group—aﬁndingconsistentwiththeA1C
results.
When the total daily insulin dose at
week 24 was compared with that at base-
line, a signiﬁcant difference was found
with a mean decrease of 18% in the etan-
ercept group compared with a 23% in-
crease in insulin usage in the placebo
group. This difference in insulin usage
wasparalleledbyanincreaseinC-peptide
AUC during a meal test in the etanercept-
treated group compared with a decline in
the placebo group, as noted above. These
results suggest that the decrease in exog-
enousinsulinusageisduetopreservation
of endogenous insulin production. The
improved metabolic control experienced
by the etanercept group is important as
patients and health care providers strive
to achieve near-normal control because it
correlates with improved clinical out-
comes (17).
Serum levels of TNF- are increased
in patients with newly diagnosed type 1
diabetes compared with those in control
subjects(18).Evenafter-cellfunctionis
completely lost, serum TNF- levels re-
mainelevatedintype1diabetes(19),sug-
gesting that the hyperglycemic state is
associated with chronic inﬂammation.
Anti-TNF-agents,includingetanercept,
have an established role in the treatment
of rheumatoid arthritis and other autoim-
muneconditions.Inanadultpatientwith
type 1 diabetes and rheumatoid arthritis,
after initiation of adalimumab (mono-
clonal antibody against TNF-), fruc-
tosamine levels decreased without any
reduction in erythrocyte sedimentation
rate and C-reactive protein or in insulin
usage (20). In another report describing
three patients with insulin resistance as
measured by the homeostasis model as-
sessment index, chronic treatment with
inﬂiximab for either rheumatoid or psori-
atic arthritis resulted in signiﬁcant im-
provement in insulin sensitivity. One
patient with type 2 diabetes reverted to a
diagnosis of impaired glucose tolerance
and stopped insulin therapy. The authors
hypothesized that TNF- blockade re-
sulted in improved insulin signaling (21).
Our ﬁndings suggest that etanercept
administration at doses customarily used
for the treatment of rheumatoid arthritis
is well tolerated in pediatric patients with
new-onset type 1 diabetes. In addition,
ourdatashowpreservationof-cellfunc-
tion with improvement in glycemic con-
trol after a 24-week course of etanercept
therapy.Althoughtheseresultsareprom-
ising, it should be recognized that pa-
tients receiving etanercept or other anti-
TNF agents must be carefully monitored
for other autoimmune conditions and in-
fections, including tuberculosis, which
occurred in 
0.007% of etanercept-
treated patients in trials enrolling
15,000patientsintheU.S.andCanada.
Infact,manyoftheagentscurrentlybeing
tested to prolong the remission period in
type 1 diabetes are likely to have signiﬁ-
cant effects on the immune system. Thus,
the goal of halting pancreatic islet -cell
demise must be weighed against possible
complications from agents that might
achieve this goal. In addition, the poten-
tial need for continuous therapy is an im-
portant factor weighing in the cost-
beneﬁt balance compared with other
potentialimmunotherapies.Forexample,
asingle14-daycourseofanti-CD3mono-
clonal antibody resulted in preserved
-cell function for at least 2 years after
onset of diabetes in 67% of subjects as-
signed to intervention compared with
26% of subjects receiving placebo. How-
ever, etanercept therapy does not require
hospitalization,andsideeffectsweremin-
imal compared with those observed dur-
ing anti-CD3 monoclonal antibody
infusion (16).
A larger study is needed to conﬁrm
these preliminary data showing that etan-
ercept may modulate the progression of
type 1 diabetes and to further address the
risk-to-beneﬁt ratio of etanercept therapy
in this population. Given the complex
pathogenesisoftype1diabetes,theuseof
etanercept in new-onset type 1 diabetes
may need to be coupled with use of an-
other agent modulating T-cells. Last,
there is a possibility that the etanercept
treatment may be explored to examine
whetheritcouldpreventordelaydiabetes
development in individuals at high risk
for the disease.
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